ArticleThe Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation2022
A novel donor-derived cell-free DNA assay for the detection of acute rejection in heart transplantation.
Article in The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 68 citations in OpenAlex.
- Precision Immunosuppression in Heart Transplantation: Biomarker-Guided Therapy Comes of Age.Current heart failure reports · 2026Review
- Serial Cardiac Troponin I Kinetics Do Not Improve Detection of Acute Cellular Rejection Beyond Concurrent Troponin Levels After Heart Transplantation.Journal of clinical medicine · 2026Article
- Identification of Heart Transplant Rejection Subtypes With Circulating MicroRNAs.Circulation. Heart failure · 2026Article
- Three-year outcomes with the use of dual non-invasive rejection surveillance after heart transplantation.JHLT open · 2026Article
- Noninvasive Biomarkers for Cardiac Allograft Rejection Monitoring: Advances, Challenges, and Future Directions.Journal of clinical medicine · 2026Review
- Advances in donor-derived cell-free DNA monitoring for solid organ transplantation.Frontiers in immunology · 2026Review
- From rejection to vasculopathy: a review of non-invasive biomarkers in alloimmune responses in heart transplantation.Frontiers in medicine · 2026Review
- Contemporary Antibody-Mediated Rejection in Heart Transplantation: JACC: Heart Failure Position Statement.JACC. Heart failure · 2025Review
- Donor-derived cell-free DNA in solid organ transplantation: analytical considerations, diagnostic performance, and clinical interpretation.Clinical transplantation and research · 2025Review
- A two-threshold algorithm using donor-derived cell-free DNA fraction and quantity to detect acute rejection after heart transplantation.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2025Article
- Transforming heart transplantation care with multi-omics insights.Journal of translational medicine · 2025Review
- Donor-Derived Cell-Free DNA Versus Left Ventricular Longitudinal Strain and Strain-Derived Myocardial Work Indices for Identification of Heart Transplant Injury.Biomedicines · 2025Article
- Advancements in noninvasive techniques for transplant rejection: from biomarker detection to molecular imaging.Journal of translational medicine · 2025Review
- Differential Effects of Brain Death and Circulatory Death on Myocardial Integrity and Transplant Outcomes.Journal of surgery and research · 2025Article
- %dd-cfDNA: The New Frontier for Heart/Lung Transplant Surveillance?Transplant international : official journal of the European Society for Organ Transplantation · 2025Review
- Right Atrial Contraction Strain Is Associated With Clinically Significant Cellular Rejection in Patients After Heart Transplantation.Transplant international : official journal of the European Society for Organ Transplantation · 2025Article
- Diagnosis of rejection following heart transplantation: diving into the future.Frontiers in transplantation · 2025Review
- Donor-Derived Cell-Free DNA in Pancreas-Kidney, Heart-Kidney, and Liver-Kidney Multiorgan Transplant Recipients (MOTR).Transplant international : official journal of the European Society for Organ Transplantation · 2025Article
- Rejection Surveillance: Integrating Cell-Free DNA and Gene Expression Panels to Decrease Invasiveness in Routine Monitoring of Heart Transplant Recipients.Methodist DeBakey cardiovascular journal · 2025Review
- Donor-derived cell-free DNA and miRNA monitoring for the early prediction and diagnosis of liver allograft rejection and patient outcomes.Frontiers in immunology · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundEndomyocardial biopsy (EMB), the reference surveillance test for acute rejection (AR) in heart transplant (HTx) recipients, is invasive, costly, and shows significant interobserver variability. Recent studies indicate that donor-derived cell-free DNA (dd-cfDNA), obtained non-invasively from blood, is associated with AR and could reduce the frequency of EMB surveillance. The aim of this study was to examine the performance characteristics of a novel test for detecting AR in adult HTx recipients.
methodsPlasma samples with contemporaneous EMBs were obtained from HTx recipients. A clinically available SNP-based massively multiplexed-PCR dd-cfDNA assay was used to measure dd-cfDNA fraction. dd-cfDNA fractions were compared with EMB-defined rejection status and test performance was assessed by constructing ROC curves and calculating accuracy measures.
resultsA total of 811 samples from 223 patients with dd-cfDNA testing and contemporaneous EMB were eligible for the study. dd-cfDNA fraction was significantly higher in AR (median 0.58%, IQR, 0.13%-1.68%) compared to non-AR (median 0.04%, IQR, 0.01%-0.11%, p
conclusionsThis novel dd-cfDNA test detects AR in HTx recipients with good accuracy and holds promise as a noninvasive test for AR in HTx recipients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.